NDA 014602 · Organon
Celestone Soluspan
Betamethasone Acetate, Betamethasone Sodium Phosphate · Injection
NovelLast checked: Nov 19, 2026Latest source record: Jul 8, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1965
Mar 3, 1965
Approved uses
1
Original approval plus efficacy supplements
Registered trials
399
91 Phase 3, 36 recruiting
FAERS reports
397
177 serious, 9 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 24, 2026.
INDICATIONS AND USAGE When oral therapy is not feasible, the intramuscular use of CELESTONE ® SOLUSPAN ® Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 3, 1965 Original approval · Type 1 - New Molecular Entity
1 products under this application
- CELESTONE SOLUSPAN · BETAMETHASONE ACETATE 3MG/ML; BETAMETHASONE SODIUM PHOSPHATE EQ 3MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Betamethasone" as an intervention, any sponsor and status, largest first.
- Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)Pivotal-lookingRecruiting
McMaster UniversityAcademic, hospital or other
NCT05114096 · 3,254 participants (planned) · Start Jul 20, 2023 · Primary completion Dec 31, 2026
Drug: Celestone + placebo; Celestone + Celestone · For: Preterm Birth; Premature Birth; Complication of Prematurity and 2 more
Sites: Calgary, Canada; Edmonton, Canada; New Westminster, Canada · 25 sites in all
- Dose Reduction of Antenatal Betamethasone Given to Prevent the Neonatal Complications Associated With Very Preterm BirthPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT02897076 · 3,250 participants · Start Jan 2017 · Primary completion Jan 5, 2020
Drug: betamethasone 24 mg; 12mg betamethasone +placebo · For: Neonatal Complications
Sites: Paris, France
- Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled TrialPivotal-lookingCompleted
The George Washington University Biostatistics CenterAcademic, hospital or other
NCT01222247 · 2,831 participants · Start Oct 2010 · Primary completion Mar 2015
Drug: Betamethasone; Placebo · For: Pregnancy; Respiratory Distress Syndrome; Pregnancy Outcomes and 1 more
Sites: Birmingham, Alabama; Stanford, California; Denver, Colorado · 17 sites in all
- Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp PsoriasisPivotal-lookingCompleted
LEO PharmaIndustry
NCT00216827 · 1,485 participants · Start Nov 2004
Drug: Calcipotriol plus betamethasone dipropionate (LEO80185 gel) · For: Psoriasis of Scalp
Sites: Québec, Canada; Roskilde, Denmark; Nice, France · 8 sites in all
- Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp PsoriasisPivotal-lookingCompleted
LEO PharmaIndustry
NCT00216840 · 1,350 participants · Start Dec 2004
Drug: Calcipotriol plus betamethasone dipropionate (LEO80185 gel) · For: Psoriasis of Scalp
Sites: Leuven, Belgium; Montreal, Canada; Turku, Finland · 7 sites in all
- LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)Pivotal-lookingCompleted
LEO PharmaIndustry
NCT01188928 · 1,152 participants · Start Sep 2010 · Primary completion Mar 2011
Drug: Calcipotriol plus betamethasone; Betamethasone-17,21-dipropionate and 2 more · For: Psoriasis Vulgaris
Sites: Mobile, Alabama; Hot Springs, Arkansas; Anaheim, California · 59 sites in all
- Phase III Randomized, Double-Blind, Placebo-Controlled Study of Antenatal Thyrotropin-Releasing Hormone in Pregnant Women With Threatened Premature DeliveryPivotal-lookingCompleted
National Center for Research Resources (NCRR)NIH
NCT00004778 · 1,090 participants · Start Aug 1993
Drug: betamethasone; dexamethasone and 1 more · For: Respiratory Distress Syndrome
- Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis VulgarisPivotal-lookingCompleted
LEO PharmaIndustry
NCT00216892 · 1,032 participants · Start Apr 2005
Drug: Calcipotriol, (calcipotriol + betamethasone) · For: Psoriasis Vulgaris
Sites: Ghent, Belgium; Hamilton, Canada; Saint-Etienne, France · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- maternal exposure during pregnancy122
- product use in unapproved indication28
- drug ineffective21
- exposure during pregnancy20
- no adverse event20
- pain17
- anxiety15
- headache14
- dizziness13
- fatigue12
- insomnia12
- anaphylactic reaction11
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 7 |
| 2005 | 19 |
| 2006 | 10 |
| 2007 | 4 |
| 2008 | 9 |
| 2009 | 16 |
| 2010 | 6 |
| 2011 | 7 |
| 2012 | 5 |
| 2013 | 16 |
| 2014 | 14 |
| 2015 | 11 |
| 2016 | 41 |
| 2017 | 24 |
| 2018 | 30 |
| 2019 | 40 |
| 2020 | 42 |
| 2021 | 37 |
| 2022 | 27 |
| 2023 | 14 |
| 2024 | 9 |
| 2025 | 3 |
| 2026 | 6 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Neurodevelopmental Outcomes After Late Preterm Antenatal Corticosteroids: The ALPS Follow-Up Study.
Gyamfi-Bannerman C, Clifton RG, Tita ATN, et al. · JAMA 2024 · Multicenter Study, Randomized Controlled Trial
- double-blind"double-bind.
Björnberg A, Hellgren L · Curr Med Res Opin 1975 · Clinical Trial, Comparative Study
- A Randomized Controlled Trial of Betamethasone on Fatigue in Patients With Advanced Cancer.
Miyazaki K, Ikenaga M, Sato T, et al. · J Pain Symptom Manage 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Antenatal Betamethasone for Women at Risk for Late Preterm Delivery.
Gyamfi-Bannerman C, Thom EA, Blackwell SC, et al. · N Engl J Med 2016 · Multicenter Study, Randomized Controlled Trial
- Peri-levator Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease-related Upper Eyelid Retraction Without Proptosis.
Awad RA, Abo-Ghadir AA, Hussien MS, et al. · Ophthalmic Plast Reconstr Surg 2024 · Randomized Controlled Trial, Comparative Study
- Microneedle transdermal delivery of compound betamethasone in alopecia areata-A randomized controlled trial.
Qiao R, Zhu J, Fang J, et al. · J Am Acad Dermatol 2025 · Randomized Controlled Trial, Comparative Study
Sponsor: Organon
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.